Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Immunome, Inc. clinical trials
The registry lists 11 studies whose lead sponsor is Immunome, Inc.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Immunome, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Immunome, Inc..
- Immunome, Inc.11 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 11 of 11.
- A Phase 1 Study of IM-1340 in Participants With Advanced CancerNot yet recruitingNCT07890246Phase 1
- A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced CancerRecruitingNCT07505771Phase 1
- A Phase 1 Study of IM-1617 in Participants With Advanced CancerRecruitingNCT07578571Phase 1
- A Phase 1 Study of IM-1021 in Participants With Advanced CancerRecruitingNCT06823167Phase 1
- A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy ParticipantsRecruitingNCT07610005Phase 1
- A Study of AL102 in Patients With Progressing Desmoid TumorsActive, not recruitingNCT04871282Phase 2/3
- A Varegacestat Hepatic Impairment StudyCompletedNCT06841315Phase 1
- A Phase 1 Mass Balance Study of VaregacestatCompletedNCT06845852Phase 1
- A Cardiac Liability Study of Varegacestat in Healthy ParticipantsCompletedNCT06855264Phase 1
- A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy ParticipantsCompletedNCT06677996Phase 1
- IMM-BCP-01 in Mild to Moderate COVID-19TerminatedNCT05429021Phase 1